Stock market today: Dow in fresh record close as Powell signals rate cut incoming
Intensity Therapeutics , Inc. (NASDAQ:INTS), a micro-cap biotech company currently valued at $8.36 million with shares trading at $0.33, held its annual meeting of stockholders via live webcast on Thursday. The company’s stock has experienced significant volatility, declining over 93% in the past year, according to InvestingPro data. According to a press release statement, 10,989,589 shares, representing approximately 59.73% of the outstanding common stock, were present in person or by proxy, constituting a quorum.
Shareholders voted on two proposals. The first was the election of Mark A. Goldberg as a Class II director to serve until the 2028 annual meeting or until a successor is elected and qualified. Goldberg received 6,979,703 votes in favor, with 222,974 votes withheld and 3,786,912 broker non-votes.
The second proposal was the ratification of the selection of EisnerAmper LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The measure received 10,929,292 votes in favor, 16,730 votes against, and 43,567 abstentions.
Intensity Therapeutics is incorporated in Delaware and its common stock is listed on The Nasdaq Stock Market LLC under the symbol INTS. The information in this article is based on a press release statement and the company’s filing with the U.S. Securities and Exchange Commission.
In other recent news, Intensity Therapeutics, Inc. announced a public offering to raise approximately $2.35 million, involving over 3 million shares of common stock and accompanying warrants. The proceeds are designated for patient enrollment in the INVINCIBLE-4 Study and ongoing treatment in the INVINCIBLE-3 Study. The company has also reported that its experimental cancer drug, INT230-6, achieved high levels of tumor necrosis in early-stage trials for triple-negative breast cancer. This development is part of their ongoing Phase 2 INVINCIBLE-4 study, which is currently recruiting participants in Switzerland and France. Benchmark has maintained a Speculative Buy rating for Intensity Therapeutics, citing progress in their clinical pipeline and recent financial results, which showed a quarterly loss improvement to $3.3 million. However, Brookline Capital Markets downgraded Intensity Therapeutics from Buy to Hold, expressing concerns over the company’s financial runway and the need for additional funding. The company is actively engaged in a Phase 3 trial for INT230-6 as a monotherapy for advanced soft tissue sarcoma, with enrollment expected to complete by the first half of 2026. These developments highlight Intensity Therapeutics’ ongoing efforts in advancing their clinical studies and addressing financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.